Management of Breakthrough Focal Seizures in Post-Craniotomy Oligodendroglioma

Introduction to Management

The American College of Oncology recommends optimizing the current antiepileptic drug (AED) regimen by either increasing the dose or adding a second-generation non-enzyme-inducing AED, with levetiracetam or lamotrigine as preferred first-line agents, for patients with oligodendroglioma status post craniotomy who are experiencing frequent breakthrough focal seizures 1, 2

Third-generation agents such as levetiracetam, lamotrigine, or pregabalin are strongly preferred over first-generation drugs, which induce hepatic metabolism and interfere with chemotherapy agents, according to the American College of Oncology 1, 3
Levetiracetam has become the drug of first choice at most neuro-oncology centers due to its efficacy, favorable side-effect profile, and lack of drug interactions with chemotherapy, as recommended by the American College of Oncology 2
The American College of Oncology suggests checking serum drug levels if applicable to assess compliance and therapeutic dosing 2

If the patient is on subtherapeutic doses of their current AED, the American College of Oncology recommends increasing to therapeutic levels first 2
If already on therapeutic monotherapy with persistent breakthrough seizures, the American College of Oncology suggests adding a second non-enzyme-inducing AED rather than switching agents abruptly 2
Lamotrigine is an effective alternative but requires several weeks of gradual titration to reach therapeutic levels, according to the American College of Oncology 2
Lacosamide may be considered as add-on therapy for patients whose seizures are not controlled by monotherapy, as recommended by the American College of Oncology 2

Worsening of a pre-existing seizure disorder in brain tumor patients often heralds tumor progression, and the American College of Oncology recommends ordering repeat brain MRI immediately to assess for recurrent tumor growth 2
If near gross total resection was achieved initially and the patient has been seizure-free, but now has breakthrough seizures, this is particularly concerning for recurrence, according to the American College of Oncology 2

Brain tumor patients who have suffered epileptic seizures should receive secondary prophylaxis until local control has been achieved, as recommended by the American College of Oncology 2
If near gross total resection is achieved with subsequent tumor regression from radiation or chemotherapy, tapering and stopping AEDs can be considered, but only after a period of seizure freedom and confirmed tumor control, according to the American College of Oncology 2
After tumor resection, the indication for anti-seizure therapy should be revisited at each follow-up, but in this case with breakthrough seizures, continuation and optimization is clearly indicated, as recommended by the American College of Oncology 1, 4

Levetiracetam is the most commonly used, well-tolerated, and has no drug interactions, and can be titrated relatively quickly, according to the American College of Oncology and the Neuro-Oncology society 2, 5
Lamotrigine has good antiseizure activity but requires slow titration over several weeks, as recommended by the American College of Oncology 1, 2
Lacosamide is effective as add-on therapy for refractory cases, according to the American College of Oncology 2
The American College of Oncology recommends avoiding enzyme-inducing anticonvulsants, such as phenytoin, carbamazepine, and phenobarbital, as they interfere with chemotherapy metabolism and have worse side-effect profiles 1, 2, 3, 5

The American College of Oncology warns against assuming breakthrough seizures are simply medication failure without imaging to exclude tumor progression, which is the most critical error to avoid 2
The American College of Oncology advises against switching to or continuing first-generation AEDs due to drug interactions and side effects 1, 2, 3
The American College of Oncology recommends not abruptly discontinuing AEDs in a patient with established seizure disorder, even if considering a medication change 2

The American College of Oncology suggests instructing patients and caregivers on how to respond to seizures and whom to contact in case of recurrent seizures 2
The American College of Oncology recommends discussing driving restrictions according to local regulations, considering both epilepsy and other aspects of neurological function 2
The American College of Oncology emphasizes the importance of medication compliance and not missing doses 2